Clinical Trials Directory

Trials / Completed

CompletedNCT07188935

Glycemia and Antibiotic Efficacy in Diabetic Recurrent UTIs

Effect of Glycemic Status on Antimicrobial Response in T2DM Patients With Recurrent UTI, Prospective Comparative Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
99 (actual)
Sponsor
Al-Mustansiriyah University · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This study looked at how blood sugar control affects treatment of repeated urinary tract infections (UTIs) in people with type 2 diabetes. Ninety-nine patients at Al-Zahraa Teaching Hospital in Iraq were included. Some patients had good blood sugar control, while others did not. All were treated with antibiotics, and doctors checked if the infection was cured after 14 days and if it came back within 30 days. The study helps show how diabetes management can affect recovery from UTIs and the chance of infection returning.

Detailed description

Recurrent urinary tract infections (rUTIs) are a frequent complication among patients with type 2 diabetes mellitus (T2DM), associated with impaired immune function, glycosuria, and increased risk of antimicrobial resistance. While UTIs are common in both diabetic and non-diabetic patients, recurrence rates and treatment failures are higher in T2DM. Few prospective studies have evaluated the effect of glycemic control on antimicrobial response in this population. This prospective comparative study enrolled 99 patients with recurrent UTIs, including 58 with T2DM, at Al-Zahraa Teaching Hospital, Wasit Province, Iraq. Patients with diabetes were stratified into groups based on glycemic control (good vs. poor). Antimicrobial therapy was administered according to hospital guidelines, and treatment response was evaluated after 14 days (clinical cure). Patients were followed for 30 days to monitor recurrence. The primary objective was to assess whether glycemic status influences antimicrobial treatment outcomes in patients with rUTIs. Secondary objectives included evaluating recurrence rates and identifying potential risk factors for treatment failure. Findings from this study highlight the importance of optimizing glycemic control as part of the overall management of recurrent UTIs in patients with T2DM.

Conditions

Interventions

TypeNameDescription
DRUGciprofloxacin 500 mg tabletAdministration of oral ciprofloxacin 500 mg twice daily for 7-14 days for the treatment of recurrent urinary tract infections in patients with type 2 diabetes mellitus, following local and international guidelines.

Timeline

Start date
2024-10-30
Primary completion
2025-06-20
Completion
2025-06-20
First posted
2025-09-23
Last updated
2025-09-24

Locations

1 site across 1 country: Iraq

Source: ClinicalTrials.gov record NCT07188935. Inclusion in this directory is not an endorsement.